Currently in phase 1b
The centerpiece of the deal is AUT00206, an oral Kv3 potassium channel modulator that is being tested in two phase 1b trials. AUT00206 advanced into the ketamine challenge study and clinical trial of schizophrenia patients on the strength of preclinical data suggesting it acts on the negative symptoms—such as apathy—and positive symptoms—such as hallucinations—associated with the condition.